Science and Medicine Group

Lab Instrumentation Markets for Pharmaceuticals & Biopharmaceuticals 2 Oct 2024

Attachments

24-008SDI Pharma-Bio Market Opportunity.pdf

Lab Instrumentation Markets for Pharmaceuticals & Biopharmaceuticals

2 Oct 2024

Request Access

Pharmacology and the development of novel therapeutics is an important part of keeping people healthy and long living. From treating basic ailments like scrapes and bruises, to tackling complex cancers and rare diseases, the importance of this industry can’t be overstated. However, creating an ideal therapeutic is not a strait forward process. An illness must be identified, and an early stage of research begins to determine what causes that illness. From here, the development of treatment begins, starting with the study of metabolic pathways, protein targets, and other key areas that may, when interacted with, help correct the ailment. The development of substances, both biological and inorganic, then proceeds. These drugs and treatments are tested for both efficacy and safety, on increasingly advanced platforms that offer more precise feedback for researchers. The best of these drug candidates are then tested in preclinical and clinical trials, translational research, and, after receiving regulatory approval, are finally manufactured and distributed, with rigorous QA/QC processes in place. Due to the nature of drugs and their interactions, mechanisms of action, side effects, the method of delivery, it’s efficacy, consistency in manufacturing, and more all must be tested using precise methods to generate accurate data. The instruments covered in this report are the primary tools for conducting that research and form the critical infrastructure for pharmaceutical and biotherapeutic compounds. Further, innovations in the instruments, software controlling them, and analysis methods will further drive new biotherapeutics and drug formulations that are key to the success of the industry.
At the heart of all drug development are the pharmaceutical, biotech, and biopharmaceutical companies conducting research and development. They account for the majority of demand for analytical and life science instruments, as they are the main commercial benefactors of new therapeutics that are brought to market. These companies will often utilize contract research organizations and public sector organizations such as academia as collaborators in R&D processes. Together, these organizations work within regional regulatory frameworks to create therapeutics to meet the growing healthcare needs of the global population. Another key partner in this framework is network of suppliers that provide instruments, consumables, equipment, and software solutions to the fast-growing pharma/bio landscape. Future growth in the pharma/bio marketplace will be driven by new therapeutic modalities that are more specific to certain disease, delivered in better ways, with faster research and production timelines, and an increased reliance on personalization to patients. The resulting price tag and need for specific capital and infrastructure will further reliance on high throughput screening, automation, and reliance on CROs and CMOs that provide expertise and scale-up resources.
The SDi 2024 Pharma/Bio Report is an in-depth examination of the major technologies used in the pharma/bio sector, encompassing 55 techniques in 8 categories. The report examines historical growth and provides forecasts for demand over the next five years. This report focuses on delivering insights into phases of discovery, therapeutic focus, and the challenges being faced in therapeutics development.

Report Overview:
Technology categories included in this report are:
• Life Science Instrumentation
• Chromatography
• Mass Spectrometry
• Lab Automation
• Atomic Spectroscopy
• Bioprocessing
• Imaging
• Other Techniques

Top Vendors include:
• Bruker
• Danaher
• Illumina
• MilliporeSigma
• Perkin Elmer
• QIAGEN
• Sartorius
• Tecan
• Thermo Fisher
• Waters